shortagewatch

Home / Companies / Hikma

Company family · HQ GB

Hikma: medicine shortages

HIK · LSE

As of 2 Nov 2026, 126 Hikma products have a reported shortage across 6 countries, covering 44 medicines.

Products short126rank #18 of 464
Medicines44active ingredients
Countries6/16
New in 90 days12+1 vs market pace
Typical duration3.4 yearsmedian so far
Manufacturing14%demand-driven 46%

Where

United States96Canada17Germany3Italy3Spain6Austria1

Which therapeutic classes

Nervous system56Cancer and immune system15Anti-infectives13Cardiovascular system12Musculoskeletal system8Dermatologicals8Digestive tract and metabolism6Various2

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
HikmaHikma: Manufacturing problem 10 (8%)8%Hikma: Increased demand 32 (25%)25%Hikma: Active ingredient shortage 9 (7%)7%Hikma: Distribution or logistics 2 (2%)Hikma: Other 16 (13%)13%Hikma: Not stated 57 (45%)45%All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

When its current shortages began

025710Dec: 0Jan ’25: 2Feb: 0FebMar: 0Apr: 1May: 3MayJun: 0Jul: 0Aug: 0AugSep: 0Oct: 0Nov: 0NovDec: 1Jan ’26: 0Feb: 0FebMar: 4Apr: 0May: 0MayJun: 3Jul: 3Aug: 3AugSep: 1Oct: 8Nov: 0Nov

Long-run trend in Canada

Canada dashboard
051015202022: 4420222023: 141420232024: 151520242025: 151520252026: 13132026

Canada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Hikma126

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Hikma: 126 / 44Hikma

Further right: more products short. Higher: more different medicines affected.

Medicines short

MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Fentanyl91 Nov 2023Not stated7/16
Lorazepam83 May 2018Increased demand5/16
Promethazine821 Nov 2023Not stated1/16
Lisdexamfetamine714 Jul 2023Active ingredient shortage5/16
Morphine73 Nov 2017Not stated8/16
Etomidate65 Oct 2022Not stated3/16
Midazolam52 Apr 2020Not stated7/16
Cefotaxime417 Feb 2015Increased demand7/16
Furosemide431 Jan 2025Not stated11/16
Lidocaine413 Jun 2018Not stated2/16
Dexamethasone38 Feb 2019Not stated1/16
Ketorolac36 Jun 2018Other4/16
Piperacillin and Beta-Lactamase Inhibitor3not givenNot stated8/16
Remifentanil328 Jun 2022Increased demand5/16
Sufentanil33 May 2022Other6/16
Vancomycin315 Jan 2025Increased demand5/16
Bendamustine218 Oct 2026Not stated7/16
Cisplatin27 Aug 2024Not stated1/16
Dopamine26 Nov 2017Increased demand2/16
Fluorouracil29 May 2023Manufacturing problem7/16
Hydromorphone21 Nov 2017Increased demand5/16
Ifosfamide212 Jun 2026Increased demand12/16
Liraglutide218 Jul 2023Not stated4/16
Methotrexate213 Mar 2023Increased demand6/16
Micafungin215 Sep 2024Manufacturing problem2/16
Rocuronium Bromide215 Feb 2023Not stated5/16
Atropine120 Dec 2023Not stated5/16
Azacitidine118 Dec 2020Increased demand6/16
Baclofen126 May 2023Distribution or logistics3/16
Carboplatin126 Oct 2026Not stated10/16
Cisatracurium113 Oct 2026Increased demand6/16
Dantrolene127 Aug 2026Increased demand3/16
Dexmedetomidine110 Apr 2020Not stated4/16
Gemcitabine15 Aug 2026Increased demand9/16
Idarubicin113 Jul 2026Other4/16
Lacosamide115 Nov 2024Manufacturing problem6/16
Levofloxacin19 Oct 2026Distribution or logistics4/16
Lidocaine, Combinations115 Sep 2026Manufacturing problem4/16
Milrinone122 Dec 2025Manufacturing problem3/16
Oxaliplatin129 Jun 2026Not stated10/16
Phenytoin131 Mar 2026Manufacturing problem3/16
Propranolol131 Oct 2023Active ingredient shortage7/16
Valproic Acid130 Dec 2020Not stated10/16
Vigabatrin116 Oct 2026Not stated1/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.